Status:

COMPLETED

Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx

Lead Sponsor:

Aichi Cancer Center

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses...

Detailed Description

OBJECTIVES: Primary * Determine the objective response of the primary tumor in patients with stage II or III squamous cell carcinoma of the larynx or hypopharynx treated with docetaxel and radiother...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed squamous cell carcinoma of the larynx or hypopharynx
  • Stage II or III disease
  • Solitary lymph node metastasis located in level II-III allowed
  • Age 70 and over OR meets 1 of the following criteria:
  • Creatinine clearance 30-60 mL/min
  • History of platinum allergy
  • Diagnosis of unstable angina
  • Ineligible for systemic chemotherapy, including high-dose platinum-containing regimens
  • PATIENT CHARACTERISTICS:
  • Age
  • See Disease Characteristics
  • Performance status
  • ECOG 0-2
  • Life expectancy
  • Not specified
  • Hematopoietic
  • WBC \> 3,000/mm\^3
  • Neutrophil count \> 1,500/mm\^3
  • Hemoglobin \> 10 g/dL
  • Platelet count \> 100,000/mm\^3
  • Hepatic
  • AST and ALT ≤ 2.0 times upper limit of normal
  • Bilirubin \< 2.0 mg/dL
  • No severe liver disease
  • Renal
  • See Disease Characteristics
  • Creatinine clearance ≥ 30 mL/min
  • No severe renal disease
  • Pulmonary
  • No severe pulmonary disease
  • Other
  • No severe neurologic disease
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Not specified
  • Chemotherapy
  • No prior systemic chemotherapy
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • No prior radiotherapy
  • Surgery
  • No prior surgery

Exclusion

    Key Trial Info

    Start Date :

    June 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    November 1 2008

    Estimated Enrollment :

    50 Patients enrolled

    Trial Details

    Trial ID

    NCT00243113

    Start Date

    June 1 2004

    End Date

    November 1 2008

    Last Update

    March 26 2013

    Active Locations (9)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (9 locations)

    1

    Aichi Cancer Center

    Nagoya, Aichi-ken, Japan, 464-8681

    2

    Hirosaki University, School of Medicine

    Hirosaki, Aomori, Japan, 036-8562

    3

    Chiba University

    Chiba, Chiba, Japan, 260-8677

    4

    Yokohama City University

    Yokohama, Kanagawa, Japan, 236-0004

    Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx | DecenTrialz